7JN Stock Chart & Stats
€0.06
€0.00(0.00%)
At close: 4:00 PM EDT
€0.06
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.03 - €0.11
Previous CloseN/A
Volume0.00
Average Volume (3M)3.00
Market Cap
€76.60M
Enterprise Value€20.18
Total Cash (Recent Filing)€7.71M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.78
Next Earnings
Sep 08, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding763,437,130
10 Day Avg. Volume10
30 Day Avg. Volume3
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)2.80
Price to Sales (P/S)0.00
P/FCF Ratio-4.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Cash Runway Supports Near-term DevelopmentThe cash position and recent fundraising provide capacity to advance key clinical programs over the next 12–18 months. This reduces immediate execution pressure and gives management time to pursue data-driven partnerships before requiring substantial additional capital.
Strong Clinical Target-engagement SignalDose-dependent cytokine suppression in a placebo-controlled human challenge study supports POLB 001’s biological rationale. Strong target engagement can improve partnering credibility and reduce development uncertainty, although patient efficacy still requires validation.
Regulatory, IP And Trial ReadinessRegulatory clearance, an operationally prepared clinical study and long-dated intellectual-property protection create a credible path toward value-generating data. These milestones strengthen asset defensibility and may improve the company’s ability to attract development partners.
Bears Say
Pre-revenue Business ModelPoolbeg has no commercial revenue to offset research and operating costs, leaving results dependent on clinical progress and future transactions. Until a program is licensed or commercialized, recurring losses will remain a central constraint on financial quality.
Persistent Cash Burn And Equity ErosionSustained operating cash consumption and cumulative losses are shrinking the equity base, limiting financial flexibility. Even with runway into 2027, larger trials and commercialization will likely require new funding, licensing proceeds or other external capital.
Dependence On Partners And Limited Clinical EvidenceThe initial study may identify a signal but cannot establish definitive efficacy as reliably as a controlled trial. Poolbeg also depends on partner interest to fund and execute later development, creating strategic and financing risk if data or negotiations disappoint.
Poolbeg Pharma Ltd. News
7JN FAQ
What was Poolbeg Pharma Ltd.’s price range in the past 12 months?
Poolbeg Pharma Ltd. lowest stock price was €0.03 and its highest was €0.11 in the past 12 months.
What is Poolbeg Pharma Ltd.’s market cap?
Poolbeg Pharma Ltd.’s market cap is €76.60M.
When is Poolbeg Pharma Ltd.’s upcoming earnings report date?
Poolbeg Pharma Ltd.’s upcoming earnings report date is Sep 08, 2026 which is in 11 days.
How were Poolbeg Pharma Ltd.’s earnings last quarter?
Poolbeg Pharma Ltd. released its earnings results on Apr 28, 2026. The company reported -€0.006 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Poolbeg Pharma Ltd. overvalued?
According to Wall Street analysts Poolbeg Pharma Ltd.’s price is currently Overvalued.
Does Poolbeg Pharma Ltd. pay dividends?
Poolbeg Pharma Ltd. does not currently pay dividends.
What is Poolbeg Pharma Ltd.’s EPS estimate?
Poolbeg Pharma Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Poolbeg Pharma Ltd. have?
Poolbeg Pharma Ltd. has 763,437,130 shares outstanding.
What happened to Poolbeg Pharma Ltd.’s price movement after its last earnings report?
Poolbeg Pharma Ltd. reported an EPS of -€0.006 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.5%.
Which hedge fund is a major shareholder of Poolbeg Pharma Ltd.?
Currently, no hedge funds are holding shares in DE:7JN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Poolbeg Pharma Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-44.05%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-2.98%
Trailing 12-Months
Company Description
Poolbeg Pharma Ltd.
Poolbeg Pharma plc is a clinical-stage biopharmaceutical company based in the United Kingdom, focused on developing treatments for infectious diseases. Its pipeline features several key programs: POLB 001, a p38 MAP Kinase inhibitor intended for severe influenza; POLB 002, a pioneering, in-licensed RNA-based immunotherapy administered intranasally to combat respiratory virus infections; and POLB 003, an intramuscular vaccine aimed at preventing Melioidosis. Beyond specific therapeutic candidates, Poolbeg also holds licensed access to advanced micro- and nanoencapsulation technology for an oral vaccine delivery system designed to stimulate gut immunity. The company further advances its research through an artificial intelligence-powered drug program. Additionally, Poolbeg is developing a biomarker platform to identify individuals at high risk of severe disease, alongside a model-derived vaccine discovery platform to pinpoint novel vaccine candidates. Incorporated in 2021, Poolbeg Pharma plc is headquartered in London.
Technical Analysis
ImmuPharma
―
Sareum Holdings
―
HemoGenyx Pharmaceuticals Plc
―
Open Orphan Plc
―
Aptamer Group Plc
―